Subjects at Risk of Parkinson's Disease in Health Checkup Examinees: Cross-sectional Analysis of Baseline Data of the NaT-PROBE Study

Overview

Journal J Neurol

Specialty Neurology

Date 2020 Feb 8

PMID 32030520

Citations 7

Authors

Makoto Hattori

Takashi Tsuboi

Katsunori Yokoi

Yasuhiro Tanaka

Maki Sato

Keisuke Suzuki

Yutaka Arahata

Akihiro Hori

Motoshi Kawashima

Akihiro Hirakawa

Yukihiko Washimi

Hirohisa Watanabe

Masahisa Katsuno

Affiliations

Soon will be listed here.

Abstract

Introduction: The present study aimed to survey the prevalence of prodromal symptoms of Parkinson's disease (PD) in Japanese health checkup examinees, for identifying at-risk subjects.

Methods: We conducted a questionnaire survey of annual health checkup examinees without neurological symptoms using the following self-reported questionnaires: Japanese version of the Scale for Outcomes in Parkinson's disease for Autonomic Symptoms (SCOPA-AUT); Self-administered Odor Question (SAOQ); REM Sleep Behavior Disorder Screening Scale (RBDSQ); Beck Depression Inventory-Second Edition (BDI-II); Epworth Sleepiness Scale (ESS); and Physical Activity Scale for the Elderly (PASE). The presence of prodromal symptoms was determined using the 90th percentile threshold of each questionnaire. Subjects ≥ 50 years of age with ≥ 2 core prodromal symptoms (dysautonomia, hyposmia, and RBD), were classified as at risk.

Results: Between March 2017 and March 2018, 4,953 participants sufficiently answered the questionnaires. Among 2,726 subjects ≥ 50 years of age, 155 were classified as at risk. These subjects had worse values of BDI-II (12.0 ± 8.3 vs. 4.4 ± 3.8, p < 0.001) and ESS (9.6 ± 5.0 vs. 6.3 ± 3.2, p < 0.001), in addition to SCOPA-AUT, SAOQ, and RBDSQ. Male at-risk subjects showed lower values of hemoglobin (14.8 ± 1.3 vs. 15.0 ± 1.1, p = 0.032) and low density lipoprotein cholesterol (114.5 ± 30.3 vs. 123.0 ± 28.9, p = 0.004) than the examinees reporting no prodromal symptoms.

Conclusion: Approximately 6% of the population aged 50 years or older was at risk for PD. Male at-risk subjects had mild hematological and metabolic changes relevant to PD.

Citing Articles

Plasma biomarkers of neurodegeneration in patients and high risk subjects with Lewy body disease.

Hiraga K, Hattori M, Satake Y, Tamakoshi D, Fukushima T, Uematsu T NPJ Parkinsons Dis. 2024; 10(1):135.

PMID: 39085262 PMC: 11292020. DOI: 10.1038/s41531-024-00745-8.

Clinico-imaging features of subjects at risk of Lewy body disease in NaT-PROBE baseline analysis.

Hattori M, Hiraga K, Satake Y, Tsuboi T, Tamakoshi D, Sato M NPJ Parkinsons Dis. 2023; 9(1):67.

PMID: 37100802 PMC: 10133289. DOI: 10.1038/s41531-023-00507-y.

Ambulatory Detection of Isolated Rapid-Eye-Movement Sleep Behavior Disorder Combining Actigraphy and Questionnaire.

Brink-Kjaer A, Gupta N, Marin E, Zitser J, Sum-Ping O, Hekmat A Mov Disord. 2022; 38(1):82-91.

PMID: 36258659 PMC: 10092688. DOI: 10.1002/mds.29249.

Association between prevalence rate of dementia with Lewy bodies and sleep characteristics in Chinese old adults.

Gan J, Liu S, Wang F, Shi Z, Lu Y, Niu J Front Hum Neurosci. 2022; 16:976753.

PMID: 36188174 PMC: 9518672. DOI: 10.3389/fnhum.2022.976753.

Wearable sensor device-based detection of decreased heart rate variability in Parkinson's disease.

Suzuki M, Nakamura T, Hirayama M, Ueda M, Hatanaka M, Harada Y J Neural Transm (Vienna). 2022; 129(10):1299-1306.

PMID: 35835890 DOI: 10.1007/s00702-022-02528-y.

References

Postuma R, Aarsland D, Barone P, Burn D, Hawkes C, Oertel W . Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord. 2012; 27(5):617-26. DOI: 10.1002/mds.24996. View

Noyce A, Lees A, Schrag A . The prediagnostic phase of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2016; 87(8):871-8. PMC: 4975823. DOI: 10.1136/jnnp-2015-311890. View

Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D . Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study. Neurology. 2014; 83(19):1739-46. PMC: 4239830. DOI: 10.1212/WNL.0000000000000960. View

Berg D, Godau J, Seppi K, Behnke S, Liepelt-Scarfone I, Lerche S . The PRIPS study: screening battery for subjects at risk for Parkinson's disease. Eur J Neurol. 2012; 20(1):102-8. DOI: 10.1111/j.1468-1331.2012.03798.x. View

Noyce A, Bestwick J, Silveira-Moriyama L, Hawkes C, Knowles C, Hardy J . PREDICT-PD: identifying risk of Parkinson's disease in the community: methods and baseline results. J Neurol Neurosurg Psychiatry. 2013; 85(1):31-7. PMC: 3888633. DOI: 10.1136/jnnp-2013-305420. View

Baig F, Lawton M, Rolinski M, Ruffmann C, Nithi K, Evetts S . Delineating nonmotor symptoms in early Parkinson's disease and first-degree relatives. Mov Disord. 2015; 30(13):1759-66. PMC: 5034839. DOI: 10.1002/mds.26281. View

Gaenslen A, Wurster I, Brockmann K, HUBER H, Godau J, Faust B . Prodromal features for Parkinson's disease--baseline data from the TREND study. Eur J Neurol. 2014; 21(5):766-72. DOI: 10.1111/ene.12382. View

Postuma R, Berg D . Advances in markers of prodromal Parkinson disease. Nat Rev Neurol. 2016; 12(11):622-634. DOI: 10.1038/nrneurol.2016.152. View

Durcan R, Wiblin L, Lawson R, Khoo T, Yarnall A, Duncan G . Prevalence and duration of non-motor symptoms in prodromal Parkinson's disease. Eur J Neurol. 2019; 26(7):979-985. PMC: 6563450. DOI: 10.1111/ene.13919. View

10.

Hughes A, Daniel S, Kilford L, Lees A . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55(3):181-4. PMC: 1014720. DOI: 10.1136/jnnp.55.3.181. View

11.

McKeith I, Dickson D, Lowe J, Emre M, OBrien J, Feldman H . Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005; 65(12):1863-72. DOI: 10.1212/01.wnl.0000187889.17253.b1. View

12.

Hagiwara A, Ito N, Sawai K, Kazuma K . Validity and reliability of the Physical Activity Scale for the Elderly (PASE) in Japanese elderly people. Geriatr Gerontol Int. 2008; 8(3):143-51. DOI: 10.1111/j.1447-0594.2008.00463.x. View

13.

Matsushima M, Yabe I, Hirotani M, Kano T, Sasaki H . Reliability of the Japanese version of the scales for outcomes in Parkinson's disease-autonomic questionnaire. Clin Neurol Neurosurg. 2014; 124:182-4. DOI: 10.1016/j.clineuro.2014.07.007. View

14.

Takebayashi H, Tsuzuki K, Oka H, Fukazawa K, Daimon T, Sakagami M . Clinical availability of a self-administered odor questionnaire for patients with olfactory disorders. Auris Nasus Larynx. 2010; 38(1):65-72. DOI: 10.1016/j.anl.2010.05.013. View

15.

Miyamoto T, Miyamoto M, Iwanami M, Kobayashi M, Nakamura M, Inoue Y . The REM sleep behavior disorder screening questionnaire: validation study of a Japanese version. Sleep Med. 2009; 10(10):1151-4. DOI: 10.1016/j.sleep.2009.05.007. View

16.

Schubert C, Cruickshanks K, Fischer M, Huang G, Klein B, Klein R . Olfactory impairment in an adult population: the Beaver Dam Offspring Study. Chem Senses. 2011; 37(4):325-34. PMC: 3325763. DOI: 10.1093/chemse/bjr102. View

17.

Mahlknecht P, Seppi K, Frauscher B, Kiechl S, Willeit J, Stockner H . Probable RBD and association with neurodegenerative disease markers: A population-based study. Mov Disord. 2015; 30(10):1417-21. DOI: 10.1002/mds.26350. View

18.

Berg D, Postuma R, Adler C, Bloem B, Chan P, Dubois B . MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2015; 30(12):1600-11. DOI: 10.1002/mds.26431. View

19.

Driver J, Logroscino G, Gaziano J, Kurth T . Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. 2009; 72(5):432-8. PMC: 2676726. DOI: 10.1212/01.wnl.0000341769.50075.bb. View

20.

Zaccai J, McCracken C, Brayne C . A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005; 34(6):561-6. DOI: 10.1093/ageing/afi190. View